Press Releases
Alzheon Announces Phase 1 Results of ALZ-801, a First-in-Class Inhibitor of Amyloid Formation and Neurotoxicity for Alzheimer’s Disease
Phase 1 data demonstrated superior properties for ALZ-801 as an optimized prodrug of tramiprosate Clinical program for ALZ-801 supported by expanded post-hoc Phase 3 analyses with tramiprosate [...]
Alzheon Announces Patent Allowance in Europe for ALZ-801 in Development for Alzheimer’s Disease
LEXINGTON, Mass., January 5, 2015 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, announced today that the European Patent Office [...]
Alzheon Appoints David Nikodem, Ph.D., to Board of Directors
LEXINGTON, Mass., January 5, 2015 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, announced today that David Nikodem, Ph.D., has joined [...]
Alzheon Announces Patent Issuance in Japan for ALZ-801 in Development for Alzheimer’s Disease
LEXINGTON, Mass., September 5, 2014 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, announced today that the Japan Patent Office [...]
Alzheon Announces Notice of Allowance for U.S. Patent for its Lead Drug Candidate ALZ-801 in Clinical Development for Alzheimer’s Disease
LEXINGTON, Mass., April 15, 2014 -- Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, announced today that the United States Patent [...]
Alzheon Announces Nomination by Industry Leaders for The Most Promising Company competition at the Personalized Medicine World Conference
LEXINGTON, Mass., January 16, 2014 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, today announced that it has been nominated [...]